Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Artelo Biosciences will present data on its lead FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain in Bangkok, October 26-30. ART26.12 is a first-in-class, orally administered, non-opioid analgesic initially targeting chemotherapy-induced peripheral neuropathy, with positive Phase 1 single-ascending-dose safety and pharmacokinetic data already reported.
Key figures
- Drug Name
- ART26.12
- Phase Of Trial
- Phase 1 (SAD complete; MAD planned)
- Next milestone
- Phase 1 multiple ascending dose (MAD) study to initiate in Q4 2026
- Phase1 sad result
- favorable safety, no serious adverse events, dose-proportional PK
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.